Astrazeneca plc (AZN) RNS Announcements

Date	Time	Date	TitleTitle (filtered)	Source
09/03/22	15:30:01	9 Mar 2022	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
07/03/22	15:30:01	7 Mar 2022	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
01/03/22	15:30:01	1 Mar 2022	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
01/03/22	15:00:01	1 Mar 2022	Total Voting Rights	Total Voting Rights	RNS
01/03/22	07:00:06	1 Mar 2022	AstraZeneca and Neurimmune close deal for NI006	AstraZeneca and Neurimmune close deal for NI006	RNS
23/02/22	07:00:02	23 Feb 2022	Filing of Form 20-F with SEC	Filing of Form 20-F with SEC	RNS
22/02/22	11:00:00	22 Feb 2022	Chair succession planning update and Annual Report	Chair succession planning update and Annual Report	RNS
21/02/22	07:00:09	21 Feb 2022	Enhertu improves PFS and OS in HER2-low BC	Enhertu improves PFS and OS in HER2-low BC	RNS
16/02/22	07:00:08	16 Feb 2022	Saphnelo approved in EU for SLE	Saphnelo approved in EU for SLE	RNS
15/02/22	07:00:06	15 Feb 2022	Lynparza combo delays progression risk in prostate	Lynparza combo delays progression risk in prostate	RNS
11/02/22	15:30:02	11 Feb 2022	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
10/02/22	07:00:03	10 Feb 2022	AZN: Full year and Q4 2021 results	AZN: Full year and Q4 2021 results	RNS
01/02/22	15:00:05	1 Feb 2022	Total Voting Rights	Total Voting Rights	RNS
19/01/22	07:05:08	19 Jan 2022	Imfinzi improves survival in biliary tract cancer	Imfinzi improves survival in biliary tract cancer	RNS
19/01/22	07:00:07	19 Jan 2022	Imfinzi combo shows unprecedented survival in HCC	Imfinzi combo shows unprecedented survival in HCC	RNS
17/01/22	07:00:07	17 Jan 2022	Enhertu granted Priority Review for breast cancer	Enhertu granted Priority Review for breast cancer	RNS
07/01/22	07:00:07	7 Jan 2022	AstraZeneca and Neurimmune sign deal for NI006	AstraZeneca and Neurimmune sign deal for NI006	RNS
05/01/22	07:00:08	5 Jan 2022	Transfer of rights to Eklira, Duaklir completed	Transfer of rights to Eklira, Duaklir completed	RNS
04/01/22	15:00:07	4 Jan 2022	Total Voting Rights	Total Voting Rights	RNS
29/12/21	07:00:11	29 Dec 2021	AstraZeneca and Ionis close eplontersen deal	AstraZeneca and Ionis close eplontersen deal	RNS
21/12/21	07:00:05	21 Dec 2021	Ultomiris accepted for FDA Priority Review for gMG	Ultomiris accepted for FDA Priority Review for gMG	RNS
20/12/21	07:05:06	20 Dec 2021	Tezspire approved in the US for severe asthma	Tezspire approved in the US for severe asthma	RNS
20/12/21	07:00:07	20 Dec 2021	Saphnelo recommended for EU approval for SLE	Saphnelo recommended for EU approval for SLE	RNS
15/12/21	15:00:01	15 Dec 2021	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
09/12/21	07:00:06	9 Dec 2021	Evusheld US FDA EUA	Evusheld US FDA EUA	RNS
07/12/21	07:00:04	7 Dec 2021	AstraZeneca, Ionis to collaborate on eplontersen	AstraZeneca, Ionis to collaborate on eplontersen	RNS
01/12/21	15:00:06	1 Dec 2021	Block listing Interim Review	Block listing Interim Review	RNS
01/12/21	15:00:06	1 Dec 2021	Total Voting Rights	Total Voting Rights	RNS
30/11/21	07:00:06	30 Nov 2021	Lynparza granted FDA Priority Review for OlympiA	Lynparza granted FDA Priority Review for OlympiA	RNS
15/11/21	16:00:05	15 Nov 2021	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
12/11/21	07:00:02	12 Nov 2021	AZN: Year to date and Q3 2021 results	AZN: Year to date and Q3 2021 results	RNS
01/11/21	15:00:01	1 Nov 2021	Total Voting Rights	Total Voting Rights	RNS
01/11/21	07:00:12	1 Nov 2021	AstraZeneca to transfer rights to Eklira, Duaklir	AstraZeneca to transfer rights to Eklira, Duaklir	RNS
25/10/21	07:00:14	25 Oct 2021	Imfinzi improved survival in biliary tract cancer	Imfinzi improved survival in biliary tract cancer	RNS
18/10/21	07:00:06	18 Oct 2021	AZ recommends ADS holders reject mini-tender offer	AZ recommends ADS holders reject mini-tender offer	RNS
15/10/21	07:00:03	15 Oct 2021	Imfinzi & tremelimumab improved OS in liver cancer	Imfinzi & tremelimumab improved OS in liver cancer	RNS
11/10/21	07:00:10	11 Oct 2021	AZD7442 PhIII trial positive in COVID outpatients	AZD7442 PhIII trial positive in COVID outpatients	RNS
04/10/21	07:00:07	4 Oct 2021	Enhertu granted BTD for breast cancer	Enhertu granted BTD for breast cancer	RNS
01/10/21	15:00:02	1 Oct 2021	Total Voting Rights	Total Voting Rights	RNS
30/09/21	16:00:07	30 Sept 2021	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
29/09/21	07:00:09	29 Sept 2021	AstraZeneca to fully acquire Caelum Biosciences	AstraZeneca to fully acquire Caelum Biosciences	RNS
28/09/21	07:00:05	28 Sept 2021	Saphnelo approved in Japan for SLE	Saphnelo approved in Japan for SLE	RNS
24/09/21	07:00:05	24 Sept 2021	Lynparza PROpel trial meets primary endpoint	Lynparza PROpel trial meets primary endpoint	RNS
23/09/21	07:00:08	23 Sept 2021	Board Committee Change	Board Committee Change	RNS
23/09/21	07:00:08	23 Sept 2021	New Sustainability Committee of the Board	New Sustainability Committee of the Board	RNS
21/09/21	07:00:09	21 Sept 2021	AstraZeneca $360m Irish manufacturing investment	AstraZeneca $360m Irish manufacturing investment	RNS
20/09/21	07:00:08	20 Sept 2021	Enhertu reduced risk of disease progression by 72%	Enhertu reduced risk of disease progression by 72%	RNS
09/09/21	16:00:04	9 Sept 2021	Imfinzi improves survival in NSCLC in POSEIDON	Imfinzi improves survival in NSCLC in POSEIDON	RNS
09/09/21	07:00:05	9 Sept 2021	PT027 PhIII asthma trials met primary endpoints	PT027 PhIII asthma trials met primary endpoints	RNS
03/09/21	07:00:06	3 Sept 2021	Ultomiris approved in EU for children with PNH	Ultomiris approved in EU for children with PNH	RNS

Showing 451–500 of 1,436 announcements

Astrazeneca plc RNS

Astrazeneca plc RNS